Nuwellis, Inc. has filed a Current Report on Form 8-K dated November 17, 2026, announcing the posting of an updated corporate presentation to its website. The filing indicates that the presentation, attached as Exhibit 99.1, is intended for use in future investor communications and conferences.
The presentation outlines the company's strategy for its Aquadex system, a clinically proven therapy for precise fluid removal in critically ill patients. Nuwellis highlights that fluid overload is associated with increased mortality and is a key driver of hospitalizations, particularly in heart failure and pediatric care. The company states that its total platform potential opportunity exceeds $4.4 billion in the U.S.
Regarding financial performance, the presentation notes year-to-date revenue growth of 13% compared to the prior year period. It also reports that gross margins improved to 72% in 2026, up from 59% in the prior year. The company claims approximately 50% of its revenues currently come from pediatric patients, with installations established in 47 leading U.S. children's hospitals.
Nuwellis details plans to expand its platform through new products and partnerships. The company submitted a 510(k) to expand the Aquadex weight indication from over 20kg to over 5kg. It is also developing Vivian, a next-generation pediatric renal support platform for patients as small as 2.5kg. Additionally, the company announced a co-promotion and distribution agreement for AtriAmp, a cardiac rhythm monitoring device, and exclusive U.S. distribution rights for Zorro-Flow, a non-invasive urine collection system for neonates. The company projects the launch of Zorro-Flow in the second half of 2027.